Search Results

You are looking at 51 - 60 of 817 items for :

  • "risk factor" x
  • Refine by Access: All x
Clear All
Full access

Jeffrey Crawford and George M. Rodgers

resistant bacteria, and do not impact the depth and duration of neutropenia, which is the major risk factor for FN. Risk Assessment Per NCCN Guidelines Before the start of chemotherapy, patients should be evaluated for their risk of FN based on

Full access

Peter F. Coccia, Alberto S. Pappo, Lynda Beaupin, Virginia F. Borges, Scott C. Borinstein, Rashmi Chugh, Shira Dinner, Jeanelle Folbrecht, A. Lindsay Frazier, Robert Goldsby, Alexandra Gubin, Robert Hayashi, Mary S. Huang, Michael P. Link, John A. Livingston, Yousif Matloub, Frederick Millard, Kevin C. Oeffinger, Diane Puccetti, Damon Reed, Steven Robinson, Abby R. Rosenberg, Tara Sanft, Holly L. Spraker-Perlman, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Nicholas Yeager, Lisa A. Gurski, and Dorothy A. Shead

adequate evaluation of the efficacy of a given treatment regimen, which in turn can invalidate the results of a clinical trial. Risk factors for nonadherence among AYA patients include patients' emotional functioning (depression and poor/low self

Full access

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Tanya Siddiqi, Judy L. Smith, Gary C. Yee, Anaadriana Zakarija, Nicole McMillian, and Maoko Naganuma

damage, and stasis from direct vascular compression. 6 - 8 The incidence of cancer-associated VTE is further increased by the presence of additional risk factors, such as acquired or congenital thrombophilia (eg, antiphospholipid syndrome, factor V

Full access

Linda S. Overholser and Carlin Callaway

cause of death for adults in the US general population, is now known to be a leading cause of death in individuals treated for cancer. 7 – 12 As with cancer, CVD in survivors could be due to common behavioral risk factors, a family history, a late

Full access

Andrew T. Kuykendall and Rami Komrokji

corresponding risk category being assigned. 2 – 4 Additional risk factors have been proposed but not universally incorporated into risk-stratification models, including cardiovascular risk factors, leukocytosis, and, perhaps most controversially, platelet count

Full access

Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma, and Dorothy A. Shead

risk factor for the development of infections in patients undergoing chemotherapy. Effective strategies to anticipate, prevent, and manage infectious complications in neutropenic patients with cancer have led to improved outcomes. 1 – 12 Because of

Full access

Judith A. Paice

. “For goal-setting surrounding pain, the focus has shifted from looking for zero on a pain scale to improving patients’ function. For a thorough assessment, we need to ask patients about risk factors for misuse. Family history is a crude proxy for risk

Full access

Noopur S. Raje, Andrew J. Yee, and G. David Roodman

3.7 years. 35 Dental extractions are a major risk factor for the development of ONJ. 34 , 36 Attention to dental hygiene and minimizing invasive procedures (eg, tooth extractions, dental implants) may reduce the risk of ONJ. 37 IMWG guidelines

Full access

Renee W. Pinsky and Mark A. Helvie

area of tissue is known as percent mammographic density ( PMD ). Breast Density Measurement Recognition of breast density as a breast cancer risk factor and measurement of density have been evolving for more than 30 years. This affects a large number

Full access

Anne K. Hubben, Nathan Pennell, Marc Shapiro, Craig Savage, and James P. Stevenson

chemotherapy initiated between January 2016 and August 2018. PP pGCSF use was appropriate if prescribed with chemotherapy regimens with a high risk (>20%) for FN, or intermediate risk (10%–20%) if other accepted FN risk factors were present. PP use with FN low